DPP-4 inhibitors have no mortality benefit in type 2 diabetes, analysis shows

Dipeptidyl peptidase-4 (DPP-4) inhibitors do not lower death rates in patients with type 2 diabetes, an analysis comparing them with other common treatments has shown.
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research